Nanobiotix Collaborates with Lianbio to Develop and Commercialize NBTXR3 in China and other Asian Countries

 Nanobiotix Collaborates with Lianbio to Develop and Commercialize NBTXR3 in China and other Asian Countries

Shots:

  • Nanobiotix to receive a $20M up front and is eligible to receive ~$220 M as contingent payments and milestones along with royalties on net sales of NBTXR3 in the licensed countries
  • LianBio to get exclusive rights to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand
  • LianBio supports the expansion of Nanobiotix’s P-III study evaluating NBTXR3 in patients with LA HNSCC by enrolling 100 patients in China. LianBio has contributed to enroll in additional 5 registrational studies conducted by Nanobiotix across multiple tumor indications and therapeutic combinations including immunotherapy

Click here to­ read full press release/ article | Ref: Nanobiotix | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post